<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04005612</url>
  </required_header>
  <id_info>
    <org_study_id>DRGS-2014-2015-165-3</org_study_id>
    <nct_id>NCT04005612</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin d and Omega 3 on Osteocalcin</brief_title>
  <official_title>Assessing the Combined Effect of Omega-3 Fatty Acid and Vitamin D3 on Plasma Osteocalcin Levels : a Randomized Controlled Trial in Males and Females With Vitamin D Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Science Private University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Applied Science Private University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing the combined effect of omega-3 fatty acid and vitamin D 3 on plasma osteocalcin
      levels
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The data about effect of vitamin D3 (VD3) and omega-3 fatty acids(omega-3FA) on plasma levels
      of osteocalcin (OCN) are scarce and conflicting and nothing is published in the literature
      about the effect of the combination of VD3 and omega-3FA on the OCN levels.

      This study was conducted to investigate effect of VD3 and omega-3FA alone and with each other
      on PLASMA OCN levels in females and males with vitamin D deficiency (VDD).

      This randomized, controlled clinical trial was designed to test effects of 50,000 IU VD3
      weekly and 300 mg omega-3FA daily for eight weeks,separately and with each other, on the
      plasma levels of OCN and 25-hydroxy vitamin D (25OHD).

      This study was conducted during winter in 86 healthy Jordanian females and males with VDD
      with a mean age of (40Â± 10) years.

      Fasting serum levels for 25OHD,OCN, PTH (parathyroid hormone),calcium, phosphate, ALT
      (alanine aminotransferase), and urea were assessed at baseline and the end of the trial .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Actual">February 1, 2020</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>vitamin d3 levels</measure>
    <time_frame>8 weeks</time_frame>
    <description>Plasma levels of 25-hydroxyvitamin D</description>
  </primary_outcome>
  <primary_outcome>
    <measure>osteocalcin levels</measure>
    <time_frame>8 weeks</time_frame>
    <description>plasma osteocalcin levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PTH</measure>
    <time_frame>8 weeks</time_frame>
    <description>Plasma concentrations of PTH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>calcium</measure>
    <time_frame>8 weeks</time_frame>
    <description>plasma Ca levels</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>vitamin d3 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weekly Dietary Supplement: Vitamin D3 50,000 IU Vitamin D3 / week for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omega3-Fatty Acid group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VD3 and Omega-3FA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50,000 IU VD3 / week and 1000 mg wild salmon and fish oil complex (contains 300 mg of omega-3 FA) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>NO INTERVENTION</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin D3</intervention_name>
    <description>50,000 IU VD3 / week for 8 weeks</description>
    <arm_group_label>VD3 and Omega-3FA group</arm_group_label>
    <arm_group_label>omega3-Fatty Acid group</arm_group_label>
    <arm_group_label>vitamin d3 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>omega-3 fatty acid</intervention_name>
    <description>300 mg of omega 3-FA once daily for 8 weeks</description>
    <arm_group_label>VD3 and Omega-3FA group</arm_group_label>
    <arm_group_label>omega3-Fatty Acid group</arm_group_label>
    <arm_group_label>vitamin d3 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin D3 and omega-3 fatty acid</intervention_name>
    <description>50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks</description>
    <arm_group_label>VD3 and Omega-3FA group</arm_group_label>
    <arm_group_label>omega3-Fatty Acid group</arm_group_label>
    <arm_group_label>vitamin d3 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control</intervention_name>
    <description>no intervention</description>
    <arm_group_label>VD3 and Omega-3FA group</arm_group_label>
    <arm_group_label>omega3-Fatty Acid group</arm_group_label>
    <arm_group_label>vitamin d3 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medical diagnosis of vitamin D deficiency (VD &lt; 30 ng / ml).

        Exclusion Criteria:

          -  People who previously diagnosed with any chronic disease such as kidney diseases were
             excluded from the study due to the effect of prolonged administration of VD3 on kidney
             stones formation.

          -  People with bone disorders also excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud S Abu-Samak, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Applied Science Private University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Applied Science University</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <reference>
    <citation>Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 2008 Apr;87(4):1080S-6S. Review.</citation>
    <PMID>18400738</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 1, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D Deficiency</keyword>
  <keyword>plama osteocalcin</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>when summary data are published</ipd_time_frame>
    <ipd_access_criteria>open access</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

